Workflow
SOFTMEDX(00648)
icon
Search documents
京玖康疗(00648) - 2023 - 中期财报
2023-11-05 10:13
Financial Performance - The company recorded revenue of HKD 26.5 million for the six months ended June 30, 2018, a decrease from HKD 83.7 million in 2017, with a gross profit of HKD 14.0 million and a gross margin of 52.9%[5] - The consolidated loss attributable to the company was HKD 40.4 million, compared to HKD 136.4 million in 2017, indicating an improvement in financial performance[5] - Revenue for the six months ended June 30, 2018, was HKD 26,520,000, a decrease of 68.3% compared to HKD 83,726,000 in 2017[27] - Gross profit for the same period was HKD 14,025,000, down 49.5% from HKD 27,737,000 in 2017[27] - The loss before tax for continuing operations was HKD 40,391,000, significantly improved from a loss of HKD 115,564,000 in the previous year[27] - The total comprehensive loss for the period was HKD 37,288,000, compared to HKD 119,450,000 in 2017, indicating a reduction of 68.9%[28] - Basic and diluted loss per share for continuing operations was HKD 12.3 cents, down from HKD 34.9 cents in the previous year[28] - The net loss attributable to owners of the company for the period was HKD 42,917,000, compared to HKD 5,894,000 in the previous year[30] - The company reported a net loss of HKD 40,400,000 for the six months ended June 30, 2018, compared to a loss of HKD 134,177,000 in the previous period[39] - The group incurred a total loss of HKD 40,391,000 for the six months ended June 30, 2018, compared to a loss of HKD 136,375,000 for the same period in 2017[44][53] Assets and Liabilities - As of June 30, 2018, the total assets and net liabilities of the group were HKD 290.3 million and HKD 65.8 million, respectively, with cash and bank balances of HKD 11.2 million[6] - Non-current assets totaled HKD 199,255,000 as of June 30, 2018, slightly decreased from HKD 200,147,000 at the end of 2017[30] - Current liabilities increased to HKD 256,302,000 from HKD 241,557,000, reflecting a rise of 6.1%[30] - The company’s total liabilities as of June 30, 2018, included a net current liability of HKD 165,200,000 and a net liability of HKD 65,800,000[39] - The group’s total liabilities increased to HKD 356,100,000 as of June 30, 2018, compared to HKD 128,368,000 as of December 31, 2017[46][56] Cash Flow - The group reported a net cash outflow of HKD 25.0 million for the six months ended June 30, 2018, compared to a net inflow of HKD 10.5 million in 2017[6] - Cash and cash equivalents decreased to HKD 11,195,000 from HKD 36,207,000, a decline of 69.0%[30] - The company experienced a net cash outflow from operating activities of HKD 22,625,000, an improvement from HKD 27,583,000 in the previous year[34] - The company’s cash flow from financing activities showed a net outflow of HKD 2,056,000, contrasting with a net inflow of HKD 41,368,000 in the previous year[34] Business Operations - The company has been actively seeking business opportunities to enhance long-term shareholder value despite challenges from the COVID-19 pandemic and other global economic factors[7] - The company aims to continue seeking new business opportunities to achieve profit growth and enhance long-term stakeholder value[7] - The company has not conducted any capital raising activities during the six months ended June 30, 2018[8] - There were no significant investments or acquisitions during the reporting period[9] - The company has terminated the consolidation of its subsidiary responsible for sports and health clubs due to loss of control, impacting its financial reporting[38] Corporate Governance - The company confirmed compliance with the corporate governance code during the six months ended June 30, 2018, except for the lack of a specified term for non-executive directors[25] - The audit committee reviewed the group's interim performance for the six months ended June 30, 2018[26] Shareholder Information - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the six months ended June 30, 2018[19] - The company did not grant any stock options during the six months ended June 30, 2018, and the total number of unexercised options as of June 30, 2018, was 29,669,346[21] - The company held 20,452,570 shares under the share award scheme as of June 30, 2018, with no awards granted during the reporting period[22] - As of June 30, 2018, the number of issued and fully paid shares is 326,037 thousand shares, amounting to HKD 3,030,660 thousand[58] - The group did not declare an interim dividend for the six months ended June 30, 2018[51] Loans and Financing - The group secured a loan of HKD 8,000,000 and another loan of HKD 12,000,000 to support its operational costs and business funding[44] - The total amount of bonds payable is HKD 20,000,000, with an interest rate ranging from 5% to 6.5%[57] - The group reported a decrease in interest expenses from HKD 16,601,000 in 2017 to HKD 10,656,000 in 2018[50] Employee Compensation - The group’s employee salaries and benefits amounted to HKD 29,474,000 for the six months ended June 30, 2018, compared to HKD 34,271,000 in 2017[50] Other Financial Metrics - The company reported a significant increase in other receivables, which rose to HKD 12,426,000 from HKD 8,776,000, an increase of 41.8%[30] - The group’s trade receivables were HKD 1,797,000 as of June 30, 2018, down from HKD 1,936,000 as of December 31, 2017[54] - The group’s total assets were HKD 290,337,000 as of June 30, 2018, compared to HKD 311,327,000 as of December 31, 2017[46][47] Legal Matters - A creditor filed for liquidation against the company in April 2023, claiming an unpaid debt of HKD 16,175,304, including interest and related costs[60]
京玖康疗(00648) - 2023 - 年度财报
2023-11-05 10:11
Financial Performance - The company recorded revenue of HKD 120.5 million for the year ended December 31, 2017, representing a 18.5% increase from HKD 101.8 million in 2016[5]. - Gross profit for the same period was HKD 46.7 million, with a gross margin of 38.8%, up from HKD 35.3 million and a gross margin of 34.7% in 2016[5]. - The consolidated loss attributable to the company was HKD 228.6 million, a significant reduction from HKD 311.4 million in 2016[5]. - The loss before tax decreased to HKD 222,235,000 in 2017 from HKD 340,276,000 in 2016, representing a 34.7% improvement[119]. - The total comprehensive loss for the year was HKD 229,135,000, a reduction from HKD 412,028,000 in 2016, indicating a 44.3% decrease[121]. - The company reported a loss attributable to owners of the company of HKD 228,594,000 for 2017, compared to HKD 311,388,000 in 2016, reflecting a 26.6% improvement[121]. - The company reported a significant loss in fair value changes of financial assets amounting to HKD 189,046,000 in 2017, compared to HKD 41,804,000 in 2016[119]. - The company reported a net loss attributable to owners of approximately HKD 228.6 million for the year ended December 31, 2017[114]. Assets and Liabilities - As of December 31, 2017, the total assets and net liabilities of the group were HKD 311.3 million and HKD 28.5 million, respectively, compared to HKD 874.1 million and HKD 319.9 million in 2016[6]. - The company had cash and cash equivalents of HKD 36.2 million as of December 31, 2017, insufficient to cover its short-term borrowings[114]. - As of December 31, 2017, the company's current liabilities amounted to HKD 130.4 million, including borrowings of HKD 200.3 million due within one year[114]. - Non-current assets decreased significantly from HKD 484,434,000 in 2016 to HKD 200,147,000 in 2017, a decline of 58.7%[124]. - Current liabilities decreased from HKD 353,328,000 in 2016 to HKD 241,557,000 in 2017, a reduction of 31.6%[124]. - The company’s equity attributable to owners decreased to HKD (5,894,000) as of December 31, 2017, from HKD 245,877,000 at the beginning of the year[125]. Cash Flow - The net cash outflow from operating activities was HKD 54.5 million, an improvement from HKD 96.5 million in 2016, while net cash inflow from investing activities was HKD 99.3 million[6]. - Cash used in operating activities was HKD 54,058,000, a decrease from HKD 95,635,000 in the previous year, reflecting a 43.4% reduction in cash outflow[127]. - The company reported a decrease in cash and cash equivalents at year-end to HKD 36,207,000 from HKD 72,943,000 at the beginning of the year, reflecting a net decrease of HKD 33,409,000[128]. - The total cash outflow from financing activities was HKD 78,151,000, contrasting with a cash inflow of HKD 147,170,000 in the previous year[128]. Business Operations and Strategy - The company has been actively seeking business opportunities to enhance long-term shareholder value despite limited resources due to prolonged trading suspension and heavy debts[19]. - The medical equipment and product distribution business has shown good progress in 2022 and 2023, despite challenges from the US-China trade conflict and the COVID-19 pandemic[19]. - The company is confident that its business will continue to thrive in 2023 and beyond as the global, Hong Kong, and Chinese economies gradually open up[19]. - The company aims to achieve profit growth and enhance long-term stakeholder value by adopting new policies and ensuring prudent financial and cash flow management[19]. - The company continues to face challenges from adverse global economic factors that may impact its operations[19]. Corporate Governance - The board of directors consists of five members with diverse skills and experience in business, law, finance, accounting, and management[70]. - The audit committee is composed entirely of independent non-executive directors and is responsible for reviewing the company's annual, interim, and quarterly financial reports[63]. - The company has complied with all code provisions of the corporate governance code, except for the non-executive directors not having a specified term[69]. - The company has established four committees under the board, including the audit committee, remuneration committee, nomination committee, and risk management committee[77]. - The remuneration committee has reviewed the remuneration of directors and senior management, finding it to be fair and reasonable[79]. Risk Management - The board has acknowledged various risks, including credit, currency, and interest rate risks, and has implemented management policies to mitigate these risks[12][15][16][17]. - The company is committed to maintaining a robust risk management system to ensure effective operations and compliance with applicable laws[86]. - The company has established a Risk Management Committee in April 2023, consisting of three members, to monitor and manage risks effectively[82]. Environmental and Social Responsibility - The company has implemented measures to minimize environmental impact, including promoting recycling and energy efficiency[93]. - The company does not generate significant harmful emissions, primarily producing non-hazardous waste, and adheres to relevant environmental regulations[92]. - The company encourages employees to participate in volunteer services and charitable work, contributing to the community[105]. - The company has a zero-tolerance policy towards child labor and forced labor, requiring all potential candidates to provide identification for verification[98]. Shareholder Information - The company did not engage in any capital raising activities during the year ended December 31, 2017[8]. - The board of directors has adopted a dividend policy aimed at ensuring continuity, stability, and sustainability, but no dividends were recommended for the year ended December 31, 2017[36]. - The company has issued at least 25% of its total issued share capital to the public as of the report date[66]. Accounting and Financial Reporting - The financial statements are prepared based on historical cost, except for certain financial instruments measured at fair value[148]. - The company failed to comply with Hong Kong Financial Reporting Standards due to incomplete accounting records[113]. - The company has not provided adequate audit evidence to confirm the accuracy of its consolidated financial statements for the year ended December 31, 2017[110]. - The application of HKFRS 15 resulted in a reclassification of HKD 60,808,000 from deferred income to contract liabilities, impacting the financial position[134]. - The company adopted HKFRS 9, which led to a reclassification of financial assets, increasing the fair value of financial assets at fair value through profit or loss to HKD 215,809,000[137].
京玖康疗(00648) - 2022 - 年度业绩
2023-05-19 14:44
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 京玖醫療健康有限公司 648 二零二一年末期業績 京玖醫療健康有限公司(「本公司」)董事會(「董事會」)現呈報本公司及其附屬公司(「本 集團」)截至二零二一年十二月三十一日止年度之經審核綜合末期業績。 ...
京玖康疗(00648) - 2022 - 年度业绩
2023-05-19 14:40
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 京玖醫療健康有限公司 648 二零二零年末期業績 京玖醫療健康有限公司(「本公司」)董事會(「董事會」)現呈報本公司及其附屬公司(「本 集團」)截至二零二零年十二月三十一日止年度之經審核綜合末期業績。 ...
京玖康疗(00648) - 2022 - 年度业绩
2023-05-19 14:36
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 京玖醫療健康有限公司 648 二零一九年末期業績 京玖醫療健康有限公司(「本公司」)董事會(「董事會」)現呈報本公司及其附屬公司(「本 集團」)截至二零一九年十二月三十一日止年度之經審核綜合末期業績。 ...
京玖康疗(00648) - 2022 - 年度业绩
2023-05-19 14:32
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 京玖醫療健康有限公司 648 二零一八年末期業績 京玖醫療健康有限公司(「本公司」)董事會(「董事會」)現呈報本公司及其附屬公司(「本 集團」)截至二零一八年十二月三十一日止年度之經審核綜合末期業績。 ...
京玖康疗(00648) - 2022 - 年度业绩
2023-05-19 14:29
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就本公告全部或任何部分 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 京玖醫療健康有限公司 648 二零一七年末期業績 京玖醫療健康有限公司(「本公司」)董事會(「董事會」)現呈報本公司及其附屬公司(「本 集團」)截至二零一七年十二月三十一日止年度之經審核綜合末期業績。 ...